What Happened?
Cambridge, MA-based Unum Therapeutics has Appointed Charles X. Wilson as Chief Executive Officer
About the Company
Unum is a Cambridge, MA-based cellular therapeutics company ushering in a new wave of innovation in cancer immunotherapy. Unum has built an antibody-coupled T-cell receptor (ACTR) platform that, when combined with tumor-specific antibodies, directs an individual’s cytotoxic T-lymphocytes (CTLs) to kill tumor cells. In contrast to other approaches that hit a single target and treat a narrow set of tumors, Unum’s approach is not restricted by antigens and may have applications for treating many types of cancers. Our lead program based on ACTR technology is expected to enter Phase I clinical testing soon to assess safety and efficacy in certain forms of leukemia and lymphoma. In parallel, we are actively seeking partners interested in using the ACTR technology to arm novel proprietary antibodies with a T-cell to improve their therapeutic potential. Working initially to pre-clinically validate antibody-ACTR combinations with partners, we expect to rapidly advance multiple proprietary combinations into clinical testing within the next few years.
About the Person
\r\n Charles "Chuck" Wilson, PhD, leads the company. Before founding Unum, Chuck led partnering for Novartis research, and was responsible for all efforts in drug discovery up through clinical Phase II development. He brings deal experience in biotech and academic collaborations, product in-licensing, spin-outs, and strategic equity investing in early stage companies. Prior to Novartis, Chuck held both scientific and business management roles in biotechnology.\r\n
Info Source
News
Short Profile